RecallDepth
Class II Terminated

Nizatidine Capsules, USP 300 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 0378-5300-93.

Company
Mylan Pharmaceuticals Inc.
Recall Initiated
January 7, 2020
Posted
January 29, 2020
Recall Number
D-0792-2020
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
16,944 bottles of 30 capsules
Firm Location
Morgantown, WV, United States

Reason for Recall

CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.

Distribution

Product was distributed to wholesalers, distributors , retail pharmacies, charitable organizations and mail order pharmacies throughout the United States and the product may have been further distributed.

Lot / Code Info

Lot # 3082876, exp. date January 2020 Lot # 3082877, exp. date January 2020

More recalls by Mylan Pharmaceuticals Inc.

View all recalls by this company →

Other recent Class II Drug recalls